$5.25 Million in Sales Expected for Kala Pharmaceuticals Inc (NASDAQ:KALA) This Quarter

Brokerages forecast that Kala Pharmaceuticals Inc (NASDAQ:KALA) will post sales of $5.25 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $4.27 million and the highest estimate coming in at $6.50 million. The business is expected to announce its next quarterly earnings report on Monday, March 9th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $12.35 million for the current financial year, with estimates ranging from $10.91 million to $14.40 million. For the next financial year, analysts anticipate that the business will post sales of $59.56 million, with estimates ranging from $35.08 million to $94.71 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.

A number of analysts recently issued reports on KALA shares. JPMorgan Chase & Co. decreased their target price on Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday. HC Wainwright decreased their target price on Kala Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Zacks Investment Research raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Wednesday. ValuEngine raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Oppenheimer set a $9.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Kala Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $17.54.

NASDAQ:KALA traded up $0.40 during trading hours on Thursday, reaching $4.11. 374,000 shares of the stock were exchanged, compared to its average volume of 249,192. The company has a market capitalization of $126.17 million, a price-to-earnings ratio of -1.66 and a beta of 2.13. The company has a quick ratio of 7.04, a current ratio of 7.50 and a debt-to-equity ratio of 1.16. Kala Pharmaceuticals has a twelve month low of $3.24 and a twelve month high of $9.25. The business has a 50-day moving average of $3.84 and a two-hundred day moving average of $5.11.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Kala Pharmaceuticals by 20.3% during the 2nd quarter. BlackRock Inc. now owns 1,684,802 shares of the company’s stock valued at $10,749,000 after acquiring an additional 283,747 shares during the last quarter. Vanguard Group Inc. raised its stake in Kala Pharmaceuticals by 25.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,237,683 shares of the company’s stock valued at $7,896,000 after acquiring an additional 248,287 shares during the last quarter. Boston Partners raised its stake in Kala Pharmaceuticals by 542.6% during the 2nd quarter. Boston Partners now owns 118,431 shares of the company’s stock valued at $756,000 after acquiring an additional 100,000 shares during the last quarter. Wedbush Securities Inc. raised its stake in Kala Pharmaceuticals by 163.9% during the 3rd quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock valued at $340,000 after acquiring an additional 55,410 shares during the last quarter. Finally, Alambic Investment Management L.P. raised its stake in Kala Pharmaceuticals by 108.0% during the 2nd quarter. Alambic Investment Management L.P. now owns 86,487 shares of the company’s stock valued at $552,000 after acquiring an additional 44,899 shares during the last quarter. 68.84% of the stock is owned by hedge funds and other institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Leave a Reply

Your email address will not be published. Required fields are marked *

*